Navigation Links
ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
Date:4/21/2009

FREDERICK, Md., April 21 /PRNewswire/ -- ImQuest BioSciences and Arisyn Therapeutics jointly announced today the successful acquisition of funding from the National Institutes of Health to support the development of novel small molecule therapeutics for the treatment of hepatitis C virus (HCV) infection. ImQuest scientists will investigate the therapeutic potential and mechanism of action of ATI-0810 (Formerly PG301029) and a series of related chemical compounds. PG301029 is a highly novel transcriptional inhibitor of HCV replication, yielding a significant reduction of viral RNA synthesis in infected cells, and laboratory studies have demonstrated the compound to be less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology studies indicate that the compound is well tolerated and has a pharmacokinetic profile appropriate for drug development. The ImQuest research team will be led by Principal Investigator Todd B. Parsley, Ph.D., Director of Hepatitis Virus Research. The funded studies will permit ImQuest to define other potent transcriptional inhibitors of HCV, investigate the mechanism of action of the active molecules and provide additional rationale for the development of a combination anti-HCV therapy using the lead molecules.

"We believe that the addition of a novel agent such as PG301029 to the current standard of care for HCV infected individuals will greatly enhance the percentage of patients that are able to achieve a robust and durable antiviral response to therapy," said Dr. Robert W. Buckheit, Jr., Executive Vice President of ImQuest. "Our data provide adequate rationale for the expedited development of PG301029 for HCV infection, and provide a platform to identify novel cellular and viral targets for future antiviral therapeutic development efforts."

The research continues the collaborative scientific partnership between ImQuest and Arisyn Therapeutics for the dev
'/>"/>

SOURCE ImQuest BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
2. ImQuest Receives Two Year Phase 2 SBIR Grant to Develop Pyrimidinedione Product as an Anti-HIV Topical Microbicide
3. ImQuest Scientists Present Important HIV Microbicide Development Results at Microbicides 2008 in Delhi, India
4. ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
5. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
6. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
7. Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
8. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
9. Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
10. YM BioSciences Announces Milestone Payment For Approval Of Nimotuzumab In The Philippines And Indonesia
11. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... May 3, 2012   Kensey Nash Corporation (Nasdaq: KNSY ... with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM ... Nash through a cash tender offer, followed by a merger with ... "We are very pleased to have entered into the ...
... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2
(Date:10/1/2014)... BOSTON (October 1, 2014) Despite a policy ... with developmental disabilities, this vulnerable population continues to ... of The Journal of the American Dental ... Medicine and Tufts University School of Dental Medicine ... factors influencing at-home oral care provided by caregivers ...
(Date:10/1/2014)... October 01, 2014 Familylifeinsurancequotes.org has ... life insurance for senior citizens. , Senior citizens ... will now sell coverage to seniors who are over ... be purchased without taking a medical examination. , Term ... online and senior clients can qualify. Having life insurance ...
(Date:10/1/2014)... Insuranceragents.info has released a new blog post ... for vulnerable family members. , Life insurance plans provide ... the family should always carry a life insurance policy ... rest of the family. , Clients can choose ... from temporary coverage or from a permanent policy. No ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog post explaining ... smokers. , Smoking will always have a negative impact ... best method to find affordable coverage. Insurance brokerage websites ... , Whole life insurance premiums will be fixed ... coverage is permanent, the initial rates are very ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... 28 Following the feature of the UltraPulse CO2 fractional laser ... Show , The Insider will also be featuring the ... and Trae Berns were interviewed today by The Insider . ... they have lived with for 20 years. The girls also discussed ...
... 28 Nuvilex, Inc. (OTC Bulletin Board: NVLX), an ... Kentrist 41 Direct, Inc. (CK41), the Company,s joint venture ... has updated its product launch plans. The previously announced ... Mr. Savage, CK41,s new Chief Executive Officer, to impart ...
... 28 Air Products, (NYSE: APD ... at www.airproducts.com/Responsibility/2009CRAR/index.asp . "In these trying times ... improved sustainability performance for our customers and our ... Products, chairman, president and chief executive officer. ...
... the American Heart Association, "silent" or "hidden" heart attacks ... are left untreated.Saint Francis Hospital in Evanston, Ill. has ... offer a new test for chest pain patients that ... The uniqueness of the new test lies in a ...
... Monday, June 1, 20091:30 to 2:30 p.m. Rooftop garden offers patients quiet haven, conservatory features ... Aurora St. Luke,s Medical Center is dedicating the Vince, ... Funds Healing Garden and the Agnes and, ... Monday, June 1, 1:30 to 2:30 p.m., WHERE: ...
... in Health Affairs finds that a Massachusetts ... has resulted in higher costs. This predictable result confirms ... must be a part of national health reform, said ... that reform is unaffordable without a public option like ...
Cached Medicine News:Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 2Health News:Miracle Treatment for Burn Scars as Seen on Today Show Will Also Be Featured on The Insider Tonight 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 2Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 3Health News:Nuvilex Gets Update from CK41 on purEffect(TM) Launch Plan 4Health News:Air Products' 2009 Corporate Responsibility Report Now Available 2Health News:Finding Hidden Heart Attacks: Saint Francis Hospital is First in Illinois to Detect Hidden Heart Attacks With New Technology 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 2Health News:Health Affairs Report On Mass. Mandatory Insurance Law Confirms: Strong Public Option Must Be Included in National Health Reform 3
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
... Afinion HbA1c test and the ... you reliable facts conveniently available ... them. Advising the patient can ... The HbA1c Test Cartridge contains ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
Medicine Products: